N/A
N=1,257
Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
Tobacco Product Beliefs and Use
Bottom Line
View on ClinicalTrials.gov: NCT06927700 ↗Enrolled (actual)
1,257
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: General Relative Harm Perception — 3.04; 2.76; 2.84; 3.19 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Modified Risk Claim Type - None (Behavioral); Product Brand - General Snus (Behavioral); Product Brand - Copenhagen (Behavioral); Modified Risk Claim Type - Multiple Diseases (Behavioral); Modified Risk Claim Type - Lung Cancer (Behavioral)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Rutgers, The State University of New Jersey
- Primary completion
- May 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY General Relative Harm Perception |
3.04; 2.76; 2.84; 3.19; 3.00; 2.97 | — |
| PRIMARY Perceptions of Perceived Relative Risks of Diseases |
3.34; 3.44; 3.33; 3.29; 3.29; 3.38 | — |
| PRIMARY Absolute Harm Perception |
3.49; 3.10; 3.43; 3.60; 3.35; 3.58 | — |
| PRIMARY Product Use Intentions |
1.52; 1.55; 1.48; 1.45; 1.41; 1.36 | — |
| SECONDARY Risk Message Recall |
25; 163; 141; 16; 145; 157 | — |
| SECONDARY Ad Persuasiveness |
3.55; 3.53; 3.37; 3.36; 3.22; 3.34 | — |
| SECONDARY Claim Believability & Credibility |
3.56; 3.88; 2.83; 3.91 | — |
| SECONDARY Overall Perceived Claim Persuasiveness |
3.51; 3.47; 2.86; 3.31 | — |
| SECONDARY Switching Comprehension |
39; 98; 83; 41; 102; 89 | — |
Summary
This study will be an online survey experiment conducted with adults who smoke cigarettes (ages 21+) to examine their reactions to modified risk advertising claims authorized by the Food & Drug Administration (FDA) for two smokeless tobacco brands (General Snus and Copenhagen), which describe the lower risks of these products compared to cigarette smoking. The study will compare effects of ads with different two different claim types (i.e. claims about reduced lung cancer risk and claims about reduced risks for multiple disease) versus ads with no reduced-risk claims, and examine effects on message and product perceptions, and interest in using the smokeless tobacco products. This study will also examine how smokers' reactions/interest may vary based on the product brand, and asses prior awareness/exposure to the authorized claims.
Eligibility Criteria
Inclusion Criteria
- Adults (age 21 and over) who are current established cigarettes smokers (i.e., smoked 100 cigarettes in their lifetime and now smoke every day or somedays), based in the US, members of Ipsos' KnowledgePanel, and have chosen to complete their research panel surveys in English
Exclusion Criteria
- Panel participants who do not meet the criteria outlined above will be excluded.
Data sourced from ClinicalTrials.gov (NCT06927700). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.